Skip to main content
Top
Published in: American Journal of Clinical Dermatology 3/2024

16-02-2024 | Alopecia | Review Article

The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature

Authors: Annika Belzer, Jolanta J. Pach, Kailyn Valido, Jonathan S. Leventhal

Published in: American Journal of Clinical Dermatology | Issue 3/2024

Login to get access

Abstract

Dermatologic adverse events resulting from oncologic therapy are common and negatively impact patients’ quality of life. Dermatologic adverse events include toxicity of the skin, oral mucosa, nails, and hair and are seen with cytotoxic chemotherapy, targeted therapy, immunotherapy, and radiation therapy, with distinct patterns of dermatologic adverse events by drug class. Here, we review the literature on the impact of dermatologic adverse events on quality of life. Studies on quality of life in patients with cancer have relied on scales such as the Dermatologic Life Quality Index and Skindex to demonstrate the association between dermatologic adverse events and declining quality of life. This relationship is likely due to a variety of factors, including physical discomfort, changes to body image, decreased self-esteem, and an effect on social interactions. Addressing such quality-of-life concerns for patients with cancer is critical, not only for patients’ well-being but also because decreased satisfaction with treatment can lead to discontinuation of treatment or dose reduction. Prophylactic treatment and early management of dermatologic adverse events by experienced dermatologists can alleviate the negative effects on quality of life and allow continuation of life-prolonging treatment.
Literature
1.
go back to reference Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285–307.PubMedPubMedCentralCrossRef Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285–307.PubMedPubMedCentralCrossRef
2.
go back to reference Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. Int J Womens Dermatol. 2020;6(5):349–56.PubMedPubMedCentralCrossRef Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. Int J Womens Dermatol. 2020;6(5):349–56.PubMedPubMedCentralCrossRef
3.
go back to reference Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl. 1):31–9.PubMedPubMedCentralCrossRef Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl. 1):31–9.PubMedPubMedCentralCrossRef
4.
go back to reference Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477–82.PubMedCrossRef Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477–82.PubMedCrossRef
5.
go back to reference Can G, Demir M, Erol O, Aydiner A. A comparison of men and women’s experiences of chemotherapy-induced alopecia. Eur J Oncol Nurs. 2013;17(3):255–60.PubMedCrossRef Can G, Demir M, Erol O, Aydiner A. A comparison of men and women’s experiences of chemotherapy-induced alopecia. Eur J Oncol Nurs. 2013;17(3):255–60.PubMedCrossRef
6.
go back to reference Barbu MA, Nitipir C, Voiosu T, Giurcaneanu C. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Rom J Intern Med. 2018;56(2):96–101.PubMed Barbu MA, Nitipir C, Voiosu T, Giurcaneanu C. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Rom J Intern Med. 2018;56(2):96–101.PubMed
7.
go back to reference Tsutsui K, Kikuchi K, Nozawa K, Takashima A, Tsuchiyama K, Namikawa K, et al. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: a multicenter, phase II trial. J Dermatol. 2021;48(7):1077–80.PubMedCrossRef Tsutsui K, Kikuchi K, Nozawa K, Takashima A, Tsuchiyama K, Namikawa K, et al. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: a multicenter, phase II trial. J Dermatol. 2021;48(7):1077–80.PubMedCrossRef
8.
go back to reference McGarvey EL, Leon-Verdin M, Baum LD, Bloomfield K, Brenin DR, Koopman C, et al. An evaluation of a computer-imaging program to prepare women for chemotherapy-related alopecia. Psychooncology. 2010;19(7):756–66.PubMedPubMedCentralCrossRef McGarvey EL, Leon-Verdin M, Baum LD, Bloomfield K, Brenin DR, Koopman C, et al. An evaluation of a computer-imaging program to prepare women for chemotherapy-related alopecia. Psychooncology. 2010;19(7):756–66.PubMedPubMedCentralCrossRef
9.
go back to reference Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17(4):317–28.PubMedCrossRef Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17(4):317–28.PubMedCrossRef
10.
go back to reference Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724–8.PubMedPubMedCentralCrossRef Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724–8.PubMedPubMedCentralCrossRef
11.
go back to reference Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103–10.PubMedCrossRef Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103–10.PubMedCrossRef
12.
go back to reference Jo SJ, Shin H, Jo S, Kwon O, Myung SK. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40(3):260–70.PubMedCrossRef Jo SJ, Shin H, Jo S, Kwon O, Myung SK. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40(3):260–70.PubMedCrossRef
13.
go back to reference Bitto FF, Konig A, Phan-Brehm T, Vallbracht T, Koch JG, Schinkothe T, et al. EVA-Scalp: evaluation of patient satisfaction with a scalp cooling device to prevent chemotherapy-induced alopecia in breast cancer patients. Breast Care (Basel). 2020;15(2):171–7.PubMedCrossRef Bitto FF, Konig A, Phan-Brehm T, Vallbracht T, Koch JG, Schinkothe T, et al. EVA-Scalp: evaluation of patient satisfaction with a scalp cooling device to prevent chemotherapy-induced alopecia in breast cancer patients. Breast Care (Basel). 2020;15(2):171–7.PubMedCrossRef
14.
go back to reference Marks DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, Isakoff SJ, Lacouture ME, et al. The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. Breast Cancer Res Treat. 2019;175(2):267–76.PubMedCrossRef Marks DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, Isakoff SJ, Lacouture ME, et al. The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. Breast Cancer Res Treat. 2019;175(2):267–76.PubMedCrossRef
15.
go back to reference Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer. 2012;20(2):395–403.PubMedCrossRef Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer. 2012;20(2):395–403.PubMedCrossRef
16.
go back to reference Urakawa R, Tarutani M, Kubota K, Uejima E. Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846–51.PubMedPubMedCentralCrossRef Urakawa R, Tarutani M, Kubota K, Uejima E. Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846–51.PubMedPubMedCentralCrossRef
17.
go back to reference Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018;50(4):1186–93.PubMedCrossRef Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018;50(4):1186–93.PubMedCrossRef
18.
go back to reference Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33.PubMedCrossRef Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33.PubMedCrossRef
19.
go back to reference Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16(10):1469–78.PubMedPubMedCentralCrossRef Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16(10):1469–78.PubMedPubMedCentralCrossRef
20.
go back to reference Fabbrocini G, Cristaudo A, Ionescu MA, Panariello L, Robert G, Pellicano M, et al. Topical non-occlusive polymers in hand-foot syndrome. G Ital Dermatol Venereol. 2018;153(2):165–71.PubMed Fabbrocini G, Cristaudo A, Ionescu MA, Panariello L, Robert G, Pellicano M, et al. Topical non-occlusive polymers in hand-foot syndrome. G Ital Dermatol Venereol. 2018;153(2):165–71.PubMed
21.
go back to reference Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, et al. Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: a preplanned analysis of the ReDOS trial. Oncologist. 2021;26(7):610–8.PubMedPubMedCentralCrossRef Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, et al. Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: a preplanned analysis of the ReDOS trial. Oncologist. 2021;26(7):610–8.PubMedPubMedCentralCrossRef
22.
go back to reference Robijns J, Lodewijckx J, Claes M, Tuts L, Lenaerts M, Wessels T, et al. Evaluation of a novel skin care product for the management of chemotherapy-related dermatologic toxicities: a quasi-experimental study. Eur J Oncol Nurs. 2023;63: 102278.PubMedCrossRef Robijns J, Lodewijckx J, Claes M, Tuts L, Lenaerts M, Wessels T, et al. Evaluation of a novel skin care product for the management of chemotherapy-related dermatologic toxicities: a quasi-experimental study. Eur J Oncol Nurs. 2023;63: 102278.PubMedCrossRef
23.
go back to reference Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010;8:40.PubMedPubMedCentralCrossRef Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010;8:40.PubMedPubMedCentralCrossRef
24.
go back to reference Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Support Care Cancer. 2018;26(4):1169–79.PubMedCrossRef Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Support Care Cancer. 2018;26(4):1169–79.PubMedCrossRef
25.
go back to reference Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21(11 Suppl. 5):34–6.PubMed Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21(11 Suppl. 5):34–6.PubMed
26.
go back to reference Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors’ perspectives. Support Care Cancer. 2010;18(11):1461–8.PubMedCrossRef Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors’ perspectives. Support Care Cancer. 2010;18(11):1461–8.PubMedCrossRef
27.
go back to reference Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, et al. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol. 2019;25(29):4007–18.PubMedPubMedCentralCrossRef Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, et al. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol. 2019;25(29):4007–18.PubMedPubMedCentralCrossRef
28.
go back to reference Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, et al. Targeted therapy-induced facial skin toxicities: impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172–7.PubMedPubMedCentralCrossRef Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, et al. Targeted therapy-induced facial skin toxicities: impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172–7.PubMedPubMedCentralCrossRef
29.
go back to reference Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24(2):513–21.PubMedCrossRef Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24(2):513–21.PubMedCrossRef
30.
go back to reference Chan JC, Lee YH, Liu CY, Shih HH, Tsay PK, Tang WR. A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res. 2019;27(6): e51.PubMedCrossRef Chan JC, Lee YH, Liu CY, Shih HH, Tsay PK, Tang WR. A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res. 2019;27(6): e51.PubMedCrossRef
31.
go back to reference Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–23.PubMedCrossRef Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–23.PubMedCrossRef
32.
go back to reference Suh Oh HJ, Florez Menendez A, Sacristan Santos V, Fernandez Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, et al. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study. Drugs Context. 2020;9. Suh Oh HJ, Florez Menendez A, Sacristan Santos V, Fernandez Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, et al. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study. Drugs Context. 2020;9.
33.
go back to reference De Tursi M, Zilli M, Carella C, Auriemma M, Lisco MN, Di Nicola M, et al. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. Onco Targets Ther. 2017;10:3007–15.PubMedPubMedCentralCrossRef De Tursi M, Zilli M, Carella C, Auriemma M, Lisco MN, Di Nicola M, et al. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. Onco Targets Ther. 2017;10:3007–15.PubMedPubMedCentralCrossRef
34.
go back to reference Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11(11):e61–5.PubMed Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11(11):e61–5.PubMed
35.
go back to reference Komatsu H, Yagasaki K, Hirata K, Hamamoto Y. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study. Eur J Oncol Nurs. 2019;38:65–9.PubMedCrossRef Komatsu H, Yagasaki K, Hirata K, Hamamoto Y. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study. Eur J Oncol Nurs. 2019;38:65–9.PubMedCrossRef
36.
go back to reference Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27(9):1712–8.PubMedPubMedCentralCrossRef Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27(9):1712–8.PubMedPubMedCentralCrossRef
37.
go back to reference Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.PubMedCrossRef Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.PubMedCrossRef
38.
go back to reference Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–7.PubMedCrossRef Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–7.PubMedCrossRef
39.
go back to reference Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158–76.PubMedCrossRef Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158–76.PubMedCrossRef
40.
go back to reference Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990–7.PubMedCrossRef Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990–7.PubMedCrossRef
41.
go back to reference Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, et al. Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatol. 2019;155(2):249–51.PubMedCrossRef Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, et al. Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatol. 2019;155(2):249–51.PubMedCrossRef
42.
go back to reference Tattersall IW, Leventhal JS. Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med. 2020;93(1):123–32.PubMedPubMedCentral Tattersall IW, Leventhal JS. Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med. 2020;93(1):123–32.PubMedPubMedCentral
43.
go back to reference Gravalos C, Sanmartin O, Gurpide A, Espana A, Majem M, Suh Oh HJ, et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2019;21(5):556–71.PubMedCrossRef Gravalos C, Sanmartin O, Gurpide A, Espana A, Majem M, Suh Oh HJ, et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2019;21(5):556–71.PubMedCrossRef
44.
go back to reference Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68.PubMedPubMedCentralCrossRef Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68.PubMedPubMedCentralCrossRef
45.
go back to reference Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713–39.PubMedCrossRef Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713–39.PubMedCrossRef
46.
go back to reference Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients’ health-related quality of life. Eur J Cancer. 2022;176:88–99.PubMedCrossRef Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients’ health-related quality of life. Eur J Cancer. 2022;176:88–99.PubMedCrossRef
47.
go back to reference Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176(6):1649–52.PubMedPubMedCentralCrossRef Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176(6):1649–52.PubMedPubMedCentralCrossRef
49.
go back to reference Beamer LC, Grant M. Longitudinal trends in skin-related and global quality of life among women with breast radiodermatitis: a pilot study. Eur J Oncol Nurs. 2018;33:22–7.PubMedCrossRef Beamer LC, Grant M. Longitudinal trends in skin-related and global quality of life among women with breast radiodermatitis: a pilot study. Eur J Oncol Nurs. 2018;33:22–7.PubMedCrossRef
50.
go back to reference Schnur JB, Ouellette SC, Dilorenzo TA, Green S, Montgomery GH. A qualitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psychooncology. 2011;20(3):260–8.PubMedPubMedCentralCrossRef Schnur JB, Ouellette SC, Dilorenzo TA, Green S, Montgomery GH. A qualitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psychooncology. 2011;20(3):260–8.PubMedPubMedCentralCrossRef
51.
go back to reference Chu CN, Hu KC, Wu RS, Bau DT. Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy. BMC Cancer. 2021;21(1):330.PubMedPubMedCentralCrossRef Chu CN, Hu KC, Wu RS, Bau DT. Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy. BMC Cancer. 2021;21(1):330.PubMedPubMedCentralCrossRef
52.
go back to reference Spalek M, Jonska-Gmyrek J, Galecki J. Radiation-induced morphea: a literature review. J Eur Acad Dermatol Venereol. 2015;29(2):197–202.PubMedCrossRef Spalek M, Jonska-Gmyrek J, Galecki J. Radiation-induced morphea: a literature review. J Eur Acad Dermatol Venereol. 2015;29(2):197–202.PubMedCrossRef
53.
go back to reference Bourgeois JF, Gourgou S, Kramar A, Lagarde JM, Guillot B. A randomized, prospective study using the LPG technique in treating radiation-induced skin fibrosis: clinical and profilometric analysis. Skin Res Technol. 2008;14(1):71–6.PubMedCrossRef Bourgeois JF, Gourgou S, Kramar A, Lagarde JM, Guillot B. A randomized, prospective study using the LPG technique in treating radiation-induced skin fibrosis: clinical and profilometric analysis. Skin Res Technol. 2008;14(1):71–6.PubMedCrossRef
54.
go back to reference Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015;141(11):1985–94.PubMedPubMedCentralCrossRef Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015;141(11):1985–94.PubMedPubMedCentralCrossRef
55.
go back to reference Beamer LC, Grant M. Skin-related quality of life among midwestern US community-based women with breast cancer experiencing radiodermatitis. Asia Pac J Oncol Nurs. 2019;6(1):50–6.PubMedPubMedCentralCrossRef Beamer LC, Grant M. Skin-related quality of life among midwestern US community-based women with breast cancer experiencing radiodermatitis. Asia Pac J Oncol Nurs. 2019;6(1):50–6.PubMedPubMedCentralCrossRef
56.
go back to reference Fuzissaki MA, Paiva CE, Oliveira MA, Lajolo Canto PP, Paiva Maia YC. The impact of radiodermatitis on breast cancer patients’ quality of life during radiotherapy: a prospective cohort study. J Pain Symptom Manage. 2019;58(1):92-9.e1.PubMedCrossRef Fuzissaki MA, Paiva CE, Oliveira MA, Lajolo Canto PP, Paiva Maia YC. The impact of radiodermatitis on breast cancer patients’ quality of life during radiotherapy: a prospective cohort study. J Pain Symptom Manage. 2019;58(1):92-9.e1.PubMedCrossRef
57.
go back to reference Lucey P, Zouzias C, Franco L, Chennupati SK, Kalnicki S, McLellan BN. Practice patterns for the prophylaxis and treatment of acute radiation dermatitis in the United States. Support Care Cancer. 2017;25(9):2857–62.PubMedCrossRef Lucey P, Zouzias C, Franco L, Chennupati SK, Kalnicki S, McLellan BN. Practice patterns for the prophylaxis and treatment of acute radiation dermatitis in the United States. Support Care Cancer. 2017;25(9):2857–62.PubMedCrossRef
58.
go back to reference Hindley A, Zain Z, Wood L, Whitehead A, Sanneh A, Barber D, et al. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2014;90(4):748–55.PubMedCrossRef Hindley A, Zain Z, Wood L, Whitehead A, Sanneh A, Barber D, et al. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2014;90(4):748–55.PubMedCrossRef
59.
go back to reference Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, et al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys. 2011;79(5):1460–6.PubMedCrossRef Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, et al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys. 2011;79(5):1460–6.PubMedCrossRef
60.
go back to reference Sekiguchi K, Sumi M, Saito A, Zenda S, Arahira S, Iino K, et al. The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis. Breast Cancer. 2023;30(1):2–12.PubMedCrossRef Sekiguchi K, Sumi M, Saito A, Zenda S, Arahira S, Iino K, et al. The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis. Breast Cancer. 2023;30(1):2–12.PubMedCrossRef
61.
go back to reference Arsenault J, Parpia S, Goldberg M, Rakovitch E, Reiter H, Doherty M, et al. Acute toxicity and quality of life of hypofractionated radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(5):943–8.PubMedCrossRef Arsenault J, Parpia S, Goldberg M, Rakovitch E, Reiter H, Doherty M, et al. Acute toxicity and quality of life of hypofractionated radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(5):943–8.PubMedCrossRef
62.
go back to reference Rossi AM, Blank NR, Nehal K, Dusza S, Lee EH. Effect of laser therapy on quality of life in patients with radiation-induced breast telangiectasias. Lasers Surg Med. 2018;50(4):284–90.PubMedCrossRef Rossi AM, Blank NR, Nehal K, Dusza S, Lee EH. Effect of laser therapy on quality of life in patients with radiation-induced breast telangiectasias. Lasers Surg Med. 2018;50(4):284–90.PubMedCrossRef
63.
go back to reference de Carvalho ESRM, Mendes FM, Degasperi GR, Pinheiro SL. Photobiomodulation for the management of xerostomia and oral mucositis in patients with cancer: a randomized clinical trial. Lasers Med Sci. 2023;38(1):101.CrossRef de Carvalho ESRM, Mendes FM, Degasperi GR, Pinheiro SL. Photobiomodulation for the management of xerostomia and oral mucositis in patients with cancer: a randomized clinical trial. Lasers Med Sci. 2023;38(1):101.CrossRef
Metadata
Title
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Authors
Annika Belzer
Jolanta J. Pach
Kailyn Valido
Jonathan S. Leventhal
Publication date
16-02-2024
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 3/2024
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-024-00847-2

Other articles of this Issue 3/2024

American Journal of Clinical Dermatology 3/2024 Go to the issue